The article you requested is

Introduction. Evaluating the Evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and Beyond

J Clin Psychiatry 2007;68(suppl 1):3-4

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Placebo-controlled efficacy trials conducted for U. S. Food and Drug Administration registration and approval purposes are an essential component of evidencebased pharmacotherapy. However, these efficacy studies have several shortcomings, including a very short duration (3–6 weeks) and rigid inclusion criteria that exclude subjects with a history of treatment resistance, coexisting medical illnesses, or comorbid substance use. Thus, the outcomes in real-world patients often fall short of the outcomes in controlled clinical trials.​